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Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver disease
worldwide, both in adults and children. It is characterized by an aberrant lipid storage in
hepatocytes, named hepatic steatosis. Simple steatosis remains a benign process in most
affected patients, while some of them develop superimposed necroinflammatory activity
with a non-specific inflammatory infiltrate and a progression to non-alcoholic steatohepati-
tis with or without fibrosis. Deep similarity and interconnections between innate immune
cells and those of liver parenchyma have been highlighted and showed to play a key role
in the development of chronic liver disease. The liver can be considered as an “immune
organ” because it hosts non-lymphoid cells, such as macrophage Kupffer cells, stellate and
dendritic cells, and lymphoid cells. Many of these cells are components of the classic innate
immune system, enabling the liver to play a major role in response to pathogens. Although
the liver provides a “tolerogenic” environment, aberrant activation of innate immune sig-
naling may trigger “harmful” inflammation that contributes to tissue injury, fibrosis, and
carcinogenesis. Pathogen recognition receptors, such as toll-like receptors and nucleotide
oligomerization domain-like receptors, are responsible for the recognition of immunogenic
signals, and represent the major conduit for sensing hepatic and non-hepatic noxious stim-
uli. A pivotal role in liver inflammation is also played by cytokines, which can initiate or have
a part in immune response, triggering hepatic intracellular signaling pathways. The sum of
inflammatory signals and deranged substrate handling induce most of the metabolic alter-
ation traits: insulin resistance, obesity, diabetes, hyperlipidemia, and their compounded
combined effects. In this review, we discuss the relevant role of innate immune cell acti-
vation in relation to NAFLD, the metabolic complications associated to this pathology, and
the possible pharmacological tools.
Keywords: NAFLD, insulin resistance, pathogen recognition receptors, innate immune cells, cytokines,
inflammation, DAMPs, pathogen-associated molecular patterns
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) represents a wide range
of pathologies beginning with simple triglyceride accumulation
inside the hepatocytes, a benign condition that can evolve and
progress to non-alcoholic steatohepatitis (NASH), characterized
by inflammation and hepatocytes injury. Disease progression
occurs together with metabolic and inflammatory derangements
that accompanied by genetic and environmental factors, promote
a persistent activation of the immune system. A complex back-
drop involves adipokines, metabolites [i.e., free fatty acids (FFAs)],
Abbreviations: AMPK, AMP-activated protein kinase; DAMPs, damage-associated
molecular pattern; FFAs, free fatty acids; HOMA-IR, homeostatic metabolic
assessment-insulin resistance; HSCs, hepatic stellate cells; IR, insulin resistance; KC,
Kupffer cells; LPS, lipopolysaccharide; NAFLD, non-alcoholic fatty liver disease;
NASH, non-alcoholic steatohepatitis; NLRs, NOD-like receptors; NOD, nucleotide
oligomerization domain; PAMPs, pathogen-associated molecular patterns; PPAR,
peroxisome proliferator-activated receptor; PRRs, pathogen recognition recep-
tors; ROS, reactive oxygen species; TGF, transforming growth factor; TIR, Toll-
interleukin-1 receptor; TLRs, toll-like receptors; TRIF, TIR-domain-containing
adapter-inducing interferon-β; UCP, uncoupling protein.
cell-derived fragments, all released by damaged cells and meta-
bolic disrupted organs, such as liver and adipose tissue (1, 2).
The innate immune system that in physiological condition main-
tains tissue and organ homeostasis, may undergo an aberrant
activation, and trigger harmful inflammation, which contributes
to initially low-grade inflammation, tissue and organ injury, and
lately fibrosis and carcinogenesis (3). A key role in the pathogen-
esis of NAFLD is played by gut-derived endotoxin, a component
of the Gram-negative bacteria wall, which reaches the liver when
the colonic mucosa is disrupted. Together with lipopolysaccharide
(LPS), other bacterial products, such as lipoproteins, flagellins, and
peptidoglycans termed pathogen-associated molecular patterns
(PAMPs), share or not similar molecular structures.
Pathogen recognition receptors (PRRs), such as toll-like recep-
tors (TLRs) and nucleotide oligomerization domain (NOD)-like
receptors (NLRs), are responsible for the recognition of immuno-
genic signals, representing a major conduit for alterations in liver.
The various types of TLRs enables to discriminate between differ-
ent PAMPs that belong to several microbial classes For instance,
TLR4 is able to recognize LPS from Gram-negative bacteria, while
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TLR2 detects Gram-positive bacteria through the recognition of
cell membrane components, i.e., lipoteichoic acid, peptidoglycan,
and various lipopetides and lipoproteins, while other TLRs, such as
3 and 7, sense viral infection binding double- and single-stranded
RNA (4). Therefore, these receptors recognized more than one lig-
and, binding even completely structural different molecules (5).
The activation of TLRs does not occur in physiological condi-
tions, conversely, when an environmental change induces tissue
injury and cell dying, endogenous protein, and non-protein lig-
ands, named damage-associated molecular pattern (DAMPs) or
alarmins (6) can bind to TLRs and induce their activation. DAMP
sources include heat shock proteins, high mobility group box 1,
breakdown products of the extracellular matrix (i.e., hyaluronan,
fibrinogen, and fibronectin), and non-protein substrates (5–7).
Also NLRs are able to recognize PAMPs and DAMPs, and are
expressed mainly on antigen-presenting cells and epithelial cells.
NLRs activation leads to the assembly of the inflammasome, con-
taining caspase-1, whose activation leads to inflammation and
apoptosis. Caspase-1, in fact is also known as interleukin cleav-
age enzyme, responsible for the conversion of prointerleukin-1,
-18, and -33 in the respective mature forms. The activation of
PRRs leads to cytokine production, contributing to liver injury and
metabolic complications. In particular TNFα and IL-6, originally
considered classical inflammatory cytokines, are now considered
major links between steatosis, insulin resistance (IR), and related
inflammatory disorders. Indeed, it has been demonstrated that
TNFα reduced insulin signaling activation (8) and its expression
in liver is enhanced in patients affected by NAFLD (9, 10). Also IL-6
has been implicated in IR, in fact is now considered its predictor or
pathogenetic marker. Moreover its expression correlates with the
degree of hepatic inflammation, and fibrosis (9, 11). Recent studies
in mouse models of NASH implicate caspase-1 and inflammasome
in inflammatory response associated to metabolic complications
(12, 13). Therefore, metabolic systems are closely integrated with
downstream pathway of TLRs and NLRs. Upon pathogens sensing
by the innate immune system, concomitantly insulin signaling and
inflammatory response are modulated as a result of the activation
of PPRs pathways, triggering both immunological and metabolic
processes (14, 15).
GUT–LIVER AXIS
The anatomical site and cellular architecture of the liver make it a
key organ in metabolic essential functions. The position between
gut and systemic circulation, guarantees that all the substances
orally ingested and absorbed by the intestine have to necessarily
pass to the liver. As a result, the liver has developed the ability
not only to receive, process, and store substances, as it occurs
in case of nutrients, but also to respond to exogenous antigenic
molecules (i.e., food, viral, bacterial, and parasitic substances).
Therefore, the liver, originally considered only a metabolic organ,
is now recognized as a mediator of systemic and local innate and
adaptive immunity. Indeed, it is continuously exposed to antigens
from the gut through the portal vein since sinusoidal endothe-
lial cells of liver parenchyma are characterized by the lack of the
basement membrane. Moreover, the liver contains a specialized
cellular repertoire able to degrade and remove toxins, exogenous
antigens, and infectious agents. This expertise allows to achieve
an immune tolerance, avoiding overactivation of immune system
or, conversely, to switch the tolerant response to a responsive state
when demanded (16–21). Therefore, the status of gut integrity
strictly accounts for the exposure of liver to gut microbiota and
antigenic food components. Translocation of large amounts of
gut-derived products is usually prevented by intact barrier systems
provided by intestinal epithelial cells (22). When the disruption
of intestinal barrier results in leaky gut, bacteria and bacterial
products easily migrate to the mesenteric lymph nodes and to
the liver. This bacterial translocation may impair liver homeosta-
sis and trigger liver inflammation, inducing the innate immune
response (3, 22, 23).
INNATE IMMUNITY AND CELL INVOLVEMENT IN NAFLD:
ROLE OF CYTOKINES
Apart from parenchymal hepatocytes, the liver also contains com-
plex repertoires of lymphoid and non-lymphoid cells, key effectors
for hepatic immunoregulation, and defense (16, 21).
Hepatic lymphoid cells comprise resident lymphocytes, dis-
tinct both in function and phenotype, from their counterparts
in the peripheral circulation and in other organs. In particular,
liver hosts conventional (i.e., B cells, CD4+ and CD8+ T cells,
natural killer cells) and non-conventional lymphoid cells (i.e., γδ
TCR+ T cells, natural killer T cells, CD4− and CD8− T cells). A
key role in specific immune function is also exerted by mucosal-
associated invariant T cells that are a highly specialized T cell
population in the vascular network of the liver (24). Regulatory
T cell populations seem to have an important role in maintaining
a beneficial balance in the liver between immuno-tolerance and
activation (25). In addition to classic parenchymal hepatocytes
and cholangiocytes, the liver contains other cell types responsible
for the homeostasis of the innate and adaptive immune system.
Among the non-lymphoid cells, Kupffer cells (KC) (26) and den-
dritic cells (27, 28) from the myeloid lineage have a major role
in the immune response. Dendritic cells are the primary antigen-
presenting cells of the liver. However, cholangiocytes can also act
as antigen-presenting cells (29), thus playing an additional role in
the hepatic immune function.
KUPFFER CELLS
Resident- or monocyte-derived KC are the largest population of
mononuclear phagocytes in the body. They are present throughout
the liver, but there is variation in the population density, cytolog-
ical characteristics, and physiologic functions of KC in different
zones of the hepatic acinus/lobule (30). During liver injury and
diseases, monocytes rapidly differentiate into mature cells that are
indistinguishable from genuine KC, independently from the cir-
culating monocytes (31). They are strategically located in liver
sinusoids, therefore they come firstly in contact with exogenous
immunoreactive material or endogenous signals (32) phagocy-
tosing, processing and presenting antigen, and secreting various
pro-inflammatory mediators such as cytokines, prostanoids, nitric
oxide, and reactive oxygen intermediates (33). Expression of the
Fc receptor results in non-specific phagocytosis of immune com-
plexes as well as antibody-coated particles such as microorganisms
and allows KC to have a significant role in control of inflamma-
tory and immunologic processes (34). Moreover, KC also express
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complement receptors for binding and phagocytosis. Bacterial
endotoxin derived from the gut or endotoxin injected in rodents
are cleared principally by the liver and taken up primarily by KC
(35). Within the liver, LPS binds to LPS-binding protein, which
then facilitates the transfer of LPS to CD14 on the surface of KC.
Signaling of LPS through CD14 is mediated by the downstream
TLR4, resulting in activation of KC and direct involvement of
the innate immune system (36). Also TLR2 has a key role in KC
response to insults, in fact TLR2-deficient KC showed an impaired
response toward microbes, such as Listeria monocytogenes (37).
After activation, KC can either avoid escalation of inflammatory
response, through a fine control of adaptive immune, or vice versa
failure to halt inflammation, properly recognizing and eliminating
danger molecules.
Generally, KC are exposed to low gut-derived LPS levels. This
stimulus allows KC to trigger an escape mechanism that involves
IL-10, which in turn contributed to the down-regulation of
pro-inflammatory cytokines (38). On the other hand, following
massive TLR4 stimulation, KC produce several chemokines and
cytokines, such as TNFα, IL-1β, IL-6, IL-12, and IL-18 (39, 40).
IL-12 and IL-18, in particular, can induce IFN-γ production by
NK cells, facilitating microbial eradication, and hepatic wound
healing (41). Thus, KC may have a higher tolerance to LPS, or a
prompt inflammatory response, adapting to the contingent cir-
cumstances. To maintain the steady state, KC are able to mount
opposite responses to exogenous triggers, polarizing to M1 or M2
subphenotypes (42). In response to TLR ligands and cytokines,
KCs undergo polarized inflammatory programs, known as M1
(classical) or M2 (alternative) activation. While the M1 phenotype
is characterized by the increase in the production of inflammatory
cytokines, and reactive nitrogen and oxygen species, associated
by microbicidal and tumoricidal activity, M2 macrophages show
immunomodulatory functions, parasite containment, and tissue
remodeling. Similarly to M1 phenotype, KC can contribute to the
pathogenesis of liver disease, increasing the production of pro-
inflammatory cytokines (e.g., TNFα) (17, 42, 43). Conversely,
adiponectin was recently shown to shift KC polarization to the
M2/anti-inflammatory phenotype (44, 45), preventing progres-
sion of NASH in mice (46). Adiponectin decrease, as well as
adiponectin gene deletion, induces hepatic steatosis progression,
fibrosis, and tumor development (47). Moreover, KCs have also
metabolic function, regulating fatty acids oxidation, increasing
hepatic lipid storage and IR, as mechanisms of adaptation to
increased caloric intake (48). This event is triggered by the secre-
tion of inflammatory cytokines (i.e., TNF, IL-6, IL-1β) (48), thus
suggesting a beneficial role for alternatively M2-activated KCs in
metabolic derangements (49, 50).
HEPATOCYTES
Hepatocytes exert metabolic and detoxifying functions, and
prompt the acute phase response. They express TLR4, even if
high doses of LPS are needed to induce significant effects (51,
52). Their expression of TLR2, rather than TLR4, is up-regulated
in inflammatory conditions, suggesting a major responsiveness to
TLR2 activation following an insult (52). Hepatocytes are able
to clear LPS from systemic circulation, through its uptake and
release into the bile, more than KCs, since KC-depleted rats have
the same capacity of LPS removal (53). TLR4, CD14, and myeloid
differentiation (MD)-2 have an obligatory role for LPS uptake by
hepatocytes. Nevertheless, TLR4 signaling does not seem to be
required for this process in vivo (54).
HEPATIC STELLATE CELLS
Hepatic stellate cells (HSCs) include around 30% of the non-
parenchymal cells (55). In physiological conditions, HSCs are
quiescent cells, and represent the largest content of vitamin A
in the body (56). When the liver is injured, damaged hepato-
cytes and immune cells start to release signal molecules that,
targeting HSCs, induce their trans-differentiation into activated
myofibroblast-like cells (55, 57, 58). Therefore, activated HSCs
switch from resting vitamin A-rich cell to proliferating, fibro-
genic, and contractile cell (58, 59), leading to hepatic fibrosis.
The main activators of their trans-differentiation are platelet-
derived growth factor and transforming growth factor (TGF)-β1,
produced by activated KC, infiltrating monocytes, platelets, and
damaged hepatocytes (60). The resting HSCs may acquire adi-
pogenic or myogenic phenotype during the trans-differentiation
(61), determined by adipogenic and myogenic gene expression.
In fact, adipogenic genes are down-regulated under ischemia
and inflammation and up-regulated by peroxisome proliferator-
activated receptor (PPAR)γ. Conversely, activated HSCs, express-
ing myogenic genes, can develop a myofibroblast-like feature,
and release extracellular matrix components, including fibrillar
collagens (collagen I and III) (62). Moreover, HSCs can also pro-
duce tissue inhibitors of metalloproteinases, which may reduce
extracellular matrix components degradation, decreasing matrix
metalloproteinases (MMPs) activities.
In addition to TGF-β1, other factors are implicated in HSCs
activation to become myofibroblastic, such as the Hedgehog (Hh)
pathway (63), cytokine stimulation (particularly TNF-α, IL-1β,
and IL-6) (64), and leptin (65). Leptin, a well-recognized pro-
fibrotic hormone, activates JAK2/STAT3 pathway following the
binding of its hepatic functional receptor, and increases the expres-
sion of tissue inhibitors of metalloproteinases, leading to matrix
deposition. Moreover, it also inhibits matrix degradation, reduc-
ing MMPs expression (66). In fact, leptin receptor expression is
low in quiescent HSCs, but increases during their transdifferen-
tiation (67). Conversely, adiponectin released from adipose tissue
reduces HSC migration and proliferation (67). Accumulating evi-
dence indicates that a role in HSC activation is also played by
renin–angiotensin system expressed in injured liver. In particu-
lar, HSCs generate de novo angiotensin 2 (68) that increases HSC
proliferation and migration, cytokine and collagen synthesis (69,
70). Finally, TLR4 contributes to the activation of HSCs through
an MyD88–NF-κB-dependent pathway (3, 71). HSCs activation in
NASH have been already reported (72), however, more studies are
needed to better clarify its role in NAFLD onset and progression.
BILIARY EPITHELIAL CELLS
Biliary epithelial cells lined the biliary tree, which carries the bile
into the intestine. As for HSCs, recently it has been demonstrated
a role for biliary epithelial cells in portal and septal fibrosis (73).
Murine biliary cells express CD14, MD-2, and TLR2, 3, 4, and
5 (74). After LPS stimulation, murine biliary cells activates the
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NF-κB pathway and synthesized TNFα (74). After TLR2 and TLR4
activation, CDX2 and mucus core protein-2 expression increased
(75). Human biliary epithelial cells express TLR1-10 (76, 77). The
progression of NAFLD in humans has been related to the increase
in bile ductules, and their senescence markers. Moreover, such
senescent bile ductules expressed chemotactic protein, such as
MCP-1, likely responsible for HSC activation (73).
HEPATIC DENDRITIC CELLS
Hepatic dendritic cells are the antigen-presenting cells in the liver.
In inflammatory conditions, they are recruited into liver sinu-
soids, and migrate to periportal and pericentral areas. They express
TLR4/MD-2 complex, produce inflammatory cytokines (i.e., IL-12
and TNFα), and express co-stimulatory molecules (CD40, CD80,
and CD86) following several stimuli, such as LPS, peptidoglycan,
poly-I:C, and cytidine-phosphateguanosine (CpG)-DNA (3). De
Creus et al. (78) found a lower expression on TLR4 in hepatic
dendritic cells compared to the spleen counterparts, suggesting a
reduced activation of hepatic adaptive immune response; on the
other hand an higher expression of TLR2 and TLR4 was shown in
hepatic dendritic cells, related to an increased production of TNFα
and IL-6 after LPS and peptidoglycan stimulation (79).
SINUSOIDAL ENDOTHELIAL CELLS
Sinusoidal endothelial cells have a major role in hepatic per-
fusion and supply, constituting the fenestrated lining of liver
sinusoids. These cells constitutively express TLR4 and CD14 and,
if acutely stimulated with LPS, NF-κB activation occurs. Con-
versely, repetitive challenge with LPS induces a reduced activation
of NF-κB pathway in these cells, associated with a reduction of
CD54 expression and leukocyte adhesion (80). TLR1-9 mRNA
was found in sinusoidal endothelial cells and functional expres-
sion of TLR3 has been demonstrated in controlling hepatitis B
virus replication by non-parenchymal liver cells (81). The role in
LPS uptake is somewhat controversial, since contrasting data were
obtained (53, 82).
PRRs: TLRs AND NLRs IN LIVER
The innate immune system is the major contributor to acute
inflammation induced by microbial infection or tissue damage
(83). Currently, 10 and 12 members of the TLR family have been
identified and ubiquitously expressed in humans and mice, respec-
tively. While TLRs sense PAMPs and DAMPs at the cell surface or
in endosomes, NLRs monitor the cytosolic compartment. TLRs,
so named for their similarity to a protein coded by Toll-gene in
the fruit fly of Drosophila, recognize signature motifs, PAMPs,
through a conserved ectodomain with leucine rich repeats, result-
ing in an alertness of immune system to the presence of microbial
antigens (84).
Being widely expressed in hepatic cells, TLRs can detect a
range of microbial structures, promoting innate and adaptive
immune responses against detected pathogens (84–87). Their sig-
naling in the liver is associated with pathological implications
in a wide range of acute or chronic liver disease. The specific
recognition, rather than non-specific as previously recognized,
by TLRs was discovered in mid-1990s and rewarded later by the
Medicine Nobel Prize laureates Bruce A. Beutler and Jules A. Hoff-
mann. Physiologically, TLR signaling induces protective responses,
such as pathogen clearance, regenerative mechanisms, and pro-
tection from cell death. Abnormal TLR signaling is associated to
hepatic damage, endotoxin shock, organ failure, impairment of
regenerative responses, fibrosis, and hepatocarcinoma (88–90).
Toll-like receptors are type I transmembrane proteins con-
taining, a part from pathogen recognition domain, transmem-
brane domains, and intracellular Toll-interleukin-1 receptor (TIR)
domains required for signaling transduction. Binding of TLRs
leads to activation of multiple pathways from an intracellular sig-
naling cascade, transcription of inflammatory genes, synthesis of
inflammatory cytokines and interferons, and cell recruitment. It
also stimulates expression of co-stimulatory molecules required to
induce an adaptive immune response of antigen-presenting cells
(66). However, evidence on mice deficient in each TLR has demon-
strated distinctive functions of these receptors in terms of PAMP
recognition and immune response (87). Microbial recognition by
TLRs occurs in several cellular compartments, such as plasma
membrane, endosomes, lysosomes, and endolysosomes. The local-
ization and trafficking of TLRs within the cell is important for
ligand accessibility, tolerance of self-molecules, and downstream
signaling transduction (84). In fact, TLRs can be grouped into
two divisions based on their subcellular localization. TLR1, 2,
4, 5, and 6 are found to be on the cell surface, while TLR 3,
7, 8, and 9 are located intracellularly and are nucleic acid sens-
ing (91). The majority of TLR family members associate with
MyD88, a common adaptor molecule, through the TIR domains,
triggering inflammatory pathways. Conversely, TLR3 and TLR4
bind another adaptor protein, TIR-domain-containing adapter-
inducing interferon-β (TRIF), to induce type I IFN. In order to
recognize LPS, TLR4 needs to recruit LPS-binding protein, CD14,
and myeloid differentiation MD-2. After TLR4 binding, the intra-
cellular domain of TLR4 recruits TIR-domain-containing adapter
protein and MyD88 for MyD88-dependent signaling, and TRIF-
related adaptor molecule binds TRIF for MyD88-independent
signaling (83, 92). TLR role, in the context of NAFLD/NASH onset
and progression, has been particularly addressed for TLR4, TLR2,
and TLR9 (93, 94).
TLR4 has been particularly studied in relation to inflammation
and fibrogenesis in liver (3). Here, KC, hit by bacterial or sterile
insults, contribute through TLR4 activation to many liver diseases
including diet-induced liver insults. Binding of LPS to TLR4 on
KC, activating NF-kB, MAPK, ERK1, p38, JNK, and IRF3, induces
the production of inflammatory cytokines and type I IFN, con-
tributing to tissue damage, increase in leukocyte infiltration, and
secretion of profibrogenic cytokines. In fact inactivation of TLR4
leads to attenuation of steatosis and NASH in several models of
experimental models (95, 96). Beyond TLR4, also TLR9 signal-
ing, induced by nuclear DNA activation, has been implicated in
NASH. This receptor in fact is able to bind CpG oligonucleotides,
contained by DNA from gut-derived bacteria. Noteworthy, bac-
terial DNA was detectable in blood from mice with diet-induced
NASH (93). Moreover, TLR9−/−mice were sheltered from NASH,
and this protection was related to a decrease in IL-1β produc-
tion by KC (93). TLR9 detrimental effect on liver was ascribed to
bone-marrow-derived cells, since mice transplanted with TLR9-
deleted bone marrow were protected by liver injury (97). TLR9
protective effect was also confirmed in other types of liver injury,
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such as I/R damage, using an inhibitory CpG sequence (97) or
in acetaminophen-induced hepatocyte death, using TLR9 antag-
onists (98). On the other hand, TLR9 can also mediate injury-
limiting pathways. It has been shown that TLR9 is involved in
dendritic cells response to DNA released from cell damage. In par-
ticular, dendritic cells respond to DAMPs through the production
of the anti-inflammatory IL-10 (97).
Lipopolysaccharide and other gut-derived bacterial products,
secondary to bacterial translocation, can stimulate TLR in the liver
(99). In this context, activation of TLRs, placed on the different
hepatic cell populations, results in acute and chronic liver diseases.
Evidence clearly showed a pivotal role for TLRs, gut microflora,
and bacterial translocation in NASH and fibrosis. Gut microbiota
has shown to modify metabolic parameter and glucose home-
ostasis in TLR2 knockout mice. In fact these mice acquired a
phenotype reminiscent of metabolic syndrome characterized by
differences in the gut microbiota (100). Moreover, the gut micro-
biota modifications observed were related to an increase in LPS
absorption, low-grade inflammation, glucose intolerance, IR, and
obesity. Interestingly, the molecular mechanisms associated to
these effects involved activation of TLR4, endoplasmic reticulum
stress, and activation of JNK (100).
Autophagy, a lysosome-dependent process of self-eating, has
recently considered as a key regulatory pathway of the innate
immune response, through effects on TLRs (101). It has
been demonstrated that Atg16L1, an autophagy gene associ-
ated with susceptibility to inflammatory bowel disease, mediat-
ing autophagosome formation regulates LPS-induced intestinal
inflammation. Consistently, macrophages lacking Atg16L1 pro-
duced increased amounts of the pro-inflammatory cytokines IL-
1β and IL-18 in response to LPS stimulation (102). Hence, failure
in macrophage macroautophagy may sustain hepatic steatosis
and liver damage. Activation of macroautophagy increases the
turnover of damaged proteins, peroxisomes, and mitochondria
(103), reducing accumulation of harmful molecules. However, it
is not known whether the impairments in autophagy, revealed in
fatty livers, involve only hepatocytes or also KC. Indeed, in steatotic
liver, the suppression of autophagy in KCs increases the sensitiv-
ity to endotoxin, suggesting a protective effect of autophagy on
progression of NAFLD (104). PAMPs and DAMPs can also be
recognized by NLR (105, 106), whose activation leads to the for-
mation of so called inflammasome. Twenty-two NLR genes have
been identified in humans thus far. The first discovered NLRs
are NOD containing proteins NOD1 and NOD2, which sense
bacterial peptidoglycan. Specifically, NOD1 recognizes the meso-
diaminopimelic acid found predominantly in Gram-negative bac-
teria, whereas NOD2 detects the muramyl dipeptide present in all
bacteria. NOD1/2 activation signals through MAPKs and NF-kB
and induces transcriptional up-regulation of pro-inflammatory
cytokines (83). Because NOD1 can recognize peptidoglycan from
the gut microbiota (107), it is possible that nutrient excess is
sensed by NOD1 through alteration of the gut microbiota and
enhanced translocation of peptidoglycan. Several NLR mem-
bers, i.e., NLRP1, NLRP3, NLRP6, and NLRC4, assemble into
large multiprotein complexes called inflammasomes to control
caspase-1 activity (108). Inflammasomes are sensors of endoge-
nous or exogenous PAMPs or DAMPs that govern cleavage of
effector pro-inflammatory cytokines (109). After a priming step,
such as infection or injury, there is an increase in inflamma-
some expression, which is then triggered by PAMPs or DAMPs
(110). Therefore, the inflammasome constitutes a platform for
the activation of caspase-1, leading to maturation of IL-1β and
IL-18 and inactivation of IL-33, regulating cell survival and
death (111).
In general, activation of TLRs and NLRs induces the production
of pro-inflammatory cytokines and the recruitment of immune
cells, such as macrophages and T lymphocytes, in the liver, as well
as other tissues, including adipose tissue, muscle, hypothalamus,
pancreatic islets, and blood vessels. The resultant chronic low-
grade inflammatory state promotes IR and energy imbalance and
contributes to the metabolic complications of obesity, such as fatty
liver disease, T2D, and atherosclerosis. The inflammasome activa-
tion has been involved in NAFLD. In particular, saturated fatty
acids induce a sensitization to LPS-induced inflammasome acti-
vation and hence liver injury. As a matter of fact, dangerous signals
are released by hepatocytes, contributing to inflammasome activa-
tion in immune cells (112). A critical determinant in the progres-
sion of NFLD toward NASH is the modulation of intestinal micro-
biota through multiple inflammasome components. Among NLR
members, the NLRP3 inflammasome has also been demonstrated
to play a critical role in diet-induced obesity and IR. Multiple stud-
ies using mice deficient in different components of the NLRP3
inflammasome (NLRP3 and caspase-1) have consistently shown
that loss of the NLRP3 inflammasome decreases HFD-induced
hepatic steatosis and inflammation (113) and improves systemic
insulin sensitivity (12, 13, 114, 115). NLRs/inflammasomes play a
role in the pathogenesis of steatosis/steatohepatitis induced in sev-
eral experimental models through alcohol (116), acetaminophen
(98), liver I/R injury (117, 118), or LPS (119, 120).
METABOLIC COMPLICATIONS AND PHARMACOLOGICAL
TOOLS
A fine regulated interaction between immunity and metabolic sys-
tem exists (14). Some tissues, such as liver and adipose tissue,
have preserved their analogy of structure during the evolutionary
process and show a specific organization of metabolic and cellular
components responsible for a direct and rapid entry into blood
vessels (121).
Liver and immune system can regulate metabolic and immune
functions by common regulatory molecular pathways and
pathogen-sensing systems. Among these, lipid-related pathways
and TLR4–NF-κβ pathway play a major role; both are activated by
metabolic, nutritional, and immunological stimuli, and can influ-
ence and regulate energy balance and IR in response to changes in
nutritional environment and inflammatory status (5, 122, 123).
Many observations point out a fine balance between immune
and metabolic systems, identifying a main role for liver. The dys-
function between these two systems is unsafe and triggers the
development of several pathologies. Overnutrition and obesity
impair metabolic homeostasis, cause stress, and arise inflam-
matory process (124, 125), contributing to the development of
the obesity-related inflammatory diseases. Conversely undernu-
trition and malnutrition suppress immune system and increase
susceptibility to infections (14).
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The condition sine qua non of NAFLD onset is macrovesicular
steatosis or fatty liver, characterized by cellular accumulation of fat,
mainly in the form of triglycerides, and sustained and amplified
by the inflammatory process. The accumulation and metabolism
of lipid in hepatocytes is under control of insulin or other hor-
mones and factors that act in autocrine and paracrine manner. In
particular, insulin potently inhibits hepatic endogenous glucose
production, which results compromised in patients with hepatic
IR (126). With its role in promoting glucose uptake, insulin has
long been considered a regulator of triglyceride catabolism by
inhibiting hormone sensitive lipase. Moreover, another important
action of insulin is its anti-lipolytic effect in adipose tissue, which
is impaired in IR, inducing an elevated release and amount of FFAs
into the bloodstream. However, IR is very common in NAFLD in
obese and diabetic subjects, but it has been evidenced also in non-
obese and non-diabetic patients (127). However, NAFLD presents
IR either in liver, impairing glucose metabolism (128), or in adi-
pose tissue, increasing lipolysis and circulating FFAs (127). All
these metabolic alterations are more evident and profound in dia-
betic patients, who are commonly characterized by an increase of
hepatic and visceral fat and IR (129).
To date, on the basis of NAFLD pathophysiology, three ther-
apeutic targets have been identified. The first two are meta-
bolic approaches, regarding IR and dyslipidemia, while the third
is focused on oxidative stress buffering. It is conceivable that
insulin sensitizers might reverse not only IR, but also liver dam-
age observed in NAFLD. Among these, the antidiabetic drug
metformin is known to reduce hepatic glucose production and
increase glucose uptake in the muscle (130). Anyway, the benefi-
cial effects of this drug on serum ALT and liver damage do not
seem to be better than those obtained from lifestyle modifica-
tions (131). Beyond metformin, the second generation thiogli-
tazones that act as agonists of PPARγ, improve insulin sensitiv-
ity and may be considered therapeutic tools for NASH, as they
are able to increase FFAs storage in subcutaneous adipocytes
rather than liver and visceral fat. Moreover, they downregulate
NF-kB and increase adiponectin levels (132). Anyway, even if
safer than first generation drugs, thioglitazones are contraindi-
cated in pediatric patients or in the presence of active liver
disease. Furthermore, another limit is their lifelong treatment,
and the possibility that, following drug cessation, steatosis might
recur (133).
Drugs used in the treatment of hyperlipoproteinemias, includ-
ing statins and fibrates, have been suggested beneficial in NAFLD
patients, reducing the degree of hepatic steatosis but not the liver
enzymes (134).
The concept of lipotoxicity and involved lipid species has been
discussed in several excellent reviews (135, 136). It has been sug-
gested that liver can accumulate the excess of FFAs as triglycerides,
which are the main lipids stored in the liver of patients with
NAFLD. In these patients, FFAs accumulation is mainly due to
several events, among these, the reduction of fatty acid oxidation,
the influx increase, and efflux reduction of fatty acids and, hence,
increased de novo lipogenesis (137).
In physiological status, hepatocytes protect themselves by
binding, transforming, catabolizing, and exporting excess FFAs.
Although large epidemiological studies suggest triglyceride-
mediated pathways might negatively affect this disease (138),
recent evidence indicates a protective function by triglycerides.
In fact, the initial increase in triglyceride synthesis could be con-
sidered a beneficial and adaptive response when hepatocytes are
exposed to elevated amount of triglyceride metabolites. Therefore,
hepatic fat accumulation cannot be considered as a pathology
or disease, but rather, as a physiologic response to increased
caloric intake (139). However, FFAs and cholesterol, especially
when accumulated in mitochondria, are considered the “proactive
and aggressive” lipids leading to TNFα-mediated liver damage and
reactive oxygen species (ROS) formation (140). These lipids could
also be present in a non-steatotic liver and act as early “inflamma-
tory” stimuli. Inflammation results in a stress response of hepato-
cytes, may lead to lipid accumulation, and therefore could precede
steatosis and NASH (141); interestingly, patients with NASH may
have no or severe steatosis, suggesting that inflammation could
take place first.
Lipid accumulation and subsequent lipotoxicity trigger intra-
cellular signaling pathways, which result in pro-inflammatory
cytokines that are responsible for cellular recruitment (Figure 1).
As above decrypted, hepatic damage is also linked to activation of
KCs, HSCs, and sinusoidal endothelial cells, which sustain inflam-
matory cytokine or mediator secretion. Most of these resident
cells are also responsive to inflammatory factors and adipokines
secreted by adipocytes. These synergic events can active vicious
cycle that amplifies inflammatory process, sustaining steatosis and
IR, leading to disease progression and hence worsening hepatic
damage (142, 143).
The synthesis of cytokines, such as TNFα and IL-6, both
involved in inflammatory and metabolic alterations, characterizes
the earliest phases of different liver injury, leading to the synthesis
of other cytokines that, jointly, induce cell migration and initiate
healing processes, including fibrosis (144). A correlation has been
found between TNF-α levels and fibrosis degree in NASH patients
(145), indeed gene expression of either TNF-α or its receptor is
significantly elevated in their hepatic and adipose tissues (146).
Similar correlation has been found in NAFLD patients, whose cir-
culating TNF-α are significantly elevated concomitantly with the
increase in the activity score, NAS, the histologic scoring system
recognized as standard reference in the evaluation and gradation
of hepatic inflammation and damage (10). As well, progression of
NAFLD correlates with polymorphisms in the TNF-α promoter
region and serum level of soluble TNF receptor 2 (147).
Infliximab, a potent TNF-α neutralizing monoclonal anti-
body used in the treatment of many chronic inflammatory dis-
eases, improves steatosis and insulin signaling both in genetic
and nutritional experimental model of IR, reducing inflamma-
tion and increasing hormonal sensitivity (148, 149). However,
using neutralizing anti-TNF antibodies in humans did not show
a clear improvement in insulin sensitivity either in rheumatoid
arthritis patients (150) or in healthy obese, but insulin resis-
tant, patients (151). Moreover, the treatment with pentoxifylline,
a TNF-α inhibitor, reduces amino-transferase serum levels and IR,
measured by homeostatic metabolic assessment-insulin resistance
(HOMA-IR) in NASH patients (152, 153). There is no doubt that
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FIGURE 1 | Cross-talk between innate immune cells during liver
inflammation: role of adipose tissue and gut. Pathogen-associated
molecular patterns (PAMPs) and damage-associated molecular patterns
(DAMPs) bind pattern recognition receptors (PRRs), including toll-like
receptors (TLRs) and NOD-like receptors (NLRs). Therefore, the liver innate
immune cells initiate and sustain hepatic inflammation process, through
inflammatory cytokine production. Impairment of intestinal mucosal barrier
and/or dysbiosis is responsible for bacterial translocation and elevated
endotoxin levels during chronic liver disease, worsening inflammation, and
inducing fibrogenesis via Toll-like receptor (TLR) signaling. Kupffer cells are hit
by bacterial or insults and contribute to the cytokine production and hepatic
stellate cell activation to maintain the balance between inflammatory and
fibrogenic signaling. Adipokines secreted from adipose tissue and
inflammatory cytokines impaired hepatic insulin signaling, leading to insulin
resistance. All these events lead to a vicious cycle that causes worsening of
liver damage, further inflammation, and disease progression.
low-grade chronic inflammation is part of NAFLD and IR but
probably other pro-inflammatory cytokines are of more relevance
in metabolic impairment. Thus, TNF-α blockade appears to have
no efficacy on IR in humans.
Most cytokine research on obesity-related diseases has centered
on IL-6, which was among the first cytokine to be implicated as
a predictor or pathogenetic marker of IR and cardiovascular dis-
ease. This cytokine plays a key role in the onset of hepatic IR,
which was found reduced in obese mice on high fat diet treated
with anti-IL-6 antibodies (154). It has been also shown that adi-
pose tissue-derived IL-6 regulates hepatic IR via up-regulation of
SOCS3 (155). Indeed, overexpression of SOCS-3 in the mouse
in the mouse liver causes IR and an increase in sterol regula-
tory element-binding protein (SREBP-1c) that regulates fatty acid
synthesis. Conversely, inhibition of SOCS3 in obese diabetic mice
improves insulin sensitivity, normalizing the increased SREBP-
1c expression (124). Recently, increased expression and activity
of SREBP pathway, responsible for de novo lipogenesis, has been
associated to high fructose exposure in mice. In particular, fructose
overconsumption, such as high fat diet, contributes to the devel-
opment of obesity, dyslipidemia, and impaired glucose tolerance,
producing advanced glycation end products (AGEs) responsi-
ble for dysfunctional proteins (156). Recently, it has shown that
high AGE levels, common in western diet, exacerbate liver injury,
inflammation and fibrosis via oxidative stress, cytokine synthe-
sis (TNFα and IL-6), and HSC activation (157). So, AGE and its
receptor pathway could be considered a new target for nutritional
or pharmacological strategy to slow NAFLD progression.
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IL-6, as well as leptin, activates AMP-activated protein kinase
(AMPK) in skeletal muscle and adipose tissue. Leptin is a lipolytic
hormone and pro-inflammatory cytokine with important effects
in regulating body weight, metabolism, and reproductive function
(158–161). Consistent with AMPK activation, IL-6 increases fat
oxidation in vitro, ex vivo, and in humans (162, 163). A definite
answer to the role of IL-6 in IR will be only possible when more
clinical data will be available on the use of IL-6-neutralizing anti-
body in diabetic and/or IR patients. To date only two small clinical
trials, however, suggest a beneficial effect. One study assessed the
influence of the antibody tocilizumab in rheumatoid arthritis
(164). In this study, 10/39 patients were diabetic. This biologi-
cal therapy resulted in a significant reduction of hemoglobin A1c,
suggesting an improvement of hyperglycemia. Similar data have
been previously obtained (165). In this small study including on
non-diabetic patients, tocilizumab treatment decreased HOMA
index significantly and improved insulin sensitivity.
An abnormal leptin secretion may contribute to switch from
insulin sensitivity to IR. Hepatic IR and high leptin concentra-
tions are two factors that favor the entry of FFAs into mitochondria
and hence the activation of PPARα. Some studies have provided
information on the liver disease progression among patients with
NASH, for example, those conducted in patients with lipodys-
trophy, a pathology characterized by reduction of peripheral fat
deposition, severe hepatic steatosis, and diabetes, all conditions
reversed by leptin administration (166).
Peroxisome proliferator-activated receptor-α is involved in
hepatic lipid metabolism, regulating the transcription of genes
encoding for enzymes involved in mitochondrial and peroxiso-
mal β-oxidation. Indeed, PPARα and peroxisomal β-oxidation
deficiency in mice confirmed the relevance of the alterations in
PPARα-inducible β-oxidation in energy metabolism and in the
development of NASH (167).
In NASH, abnormalities in ultrastructure of mitochondria and
in peroxidation of plasma/mitochondrial membranes have been
described. These modifications induce decreased mitochondr-
ial respiration and impaired ATP generation capacity, leading to
mega-mitochondria formation and cell death (168, 169). These
alterations were correlated with serum TNFα, IR, and body weight.
Moreover, increased mitochondrial ROS can increase hepatocyte
Fas-ligand expression with a consequent activation of apoptotic
mechanism of hepatocyte death (170). Lower levels of serum
antioxidants are present in patients with NASH. Depletion of
antioxidants via lipid peroxidation and free oxygen radical species
renders the liver more susceptible to oxidative damage. In fact,
treatment with various antioxidants, i.e., glutathione prodrugs
(S-adenosylmethionine, betaine, choline), vitamin E, silymarin,
decreasing production of ROS reduces steatosis in rats on choline-
and methionine-deficient diets or high fat diet (171, 172). Also
alpha lipoic acid, a naturally occurring thiol antioxidant, showed
a hepatoprotective effect, associated with reduced expression of
cytochrome P2E1, endoplasmic reticulum stress, and reduction
of mitogen-activated protein kinases and NF-κB activity in mice
on choline- and methionine-deficient diet (173). However, sev-
eral clinical trials of putative antioxidants have been performed in
patients with NASH (174–176).
Probiotics, short chain fatty acids, and intervention on gut
flora positively prevent liver fat accumulation and inflammation
in leptin-deficient mice (149) or rats on high fat diet (161, 177).
The therapeutic effect of probiotics might be related to a variety of
direct and indirect mechanisms, including modification of local
microbiota, epithelial barrier function, intestinal inflammation,
oxidative stress, or the modulation of immune system (178). Very
recently, we studied the effect of butyrate and its synthetic amide
derivative on diet-induced NAFLD in rats. The mechanisms of
the therapeutic butyrate effect were related to prevention of liver
inflammation and damage, steatosis, onset of IR, and imbalance
of TLRs pattern in the early stage of NAFLD (177). Butyrate is
known to have several distinct mechanisms of action. Among
these, the epigenetic mechanism involves the hyperacetylation
of histones, by inhibiting class I and class II histone deacety-
lases and regulating gene transcription and transcription factor
activity (179).
In liver, the uncoupling protein (UCP)2 plays a key role in
the adaptive response that preserves the hepatocytes viability in
steatotic livers, but it also makes these cells more vulnerable to fur-
ther insults. Although UCP is barely detectable in hepatocytes from
normal adults (180), hepatic synthesis of UCP-2 increases after
the induction of PPARα in these cells (181). The expression and
activity of UCP-2 increased in hepatocytes from leptin-deficient
mice (182) and from some patients with NASH or alcoholic
hepatitis (183). Increased UCP-2 in mitochondria depolarizes the
inner mitochondrial membrane, and augments the activity of the
electron-transport chain, reducing the superoxide anion forma-
tion and calcium accumulation (184). It has been suggested that
increased synthesis of UCP-2 in steatotic liver may contribute to
inhibition of hepatocyte apoptosis (185), explaining why the acti-
vation of PPARα increases the survival of these cells. It is notable
that cells with increased UCP activity show partially depolarized
mitochondria and major vulnerability to loss of the mitochon-
drial inner membrane potential, when exposed to further insults
(i.e., TNFα and endotoxin), with consequent depletion of ATP and
necrosis (186–188).
The anatomical position of liver between the gut and the
systemic circulation and hepatic cellular architecture is clearly
responsible for its failure to detoxify endotoxins absorbed from
portal circulation after hepatic injury. It might lead to further
liver damage and escape of detrimental substances into the general
circulation. In advanced stages of NAFLD, as shown in cirrhotic
patients, gut-derived products can be involved in the activation of
cytokine cascades and subsequent IR (189).
Not only bacterial products from the intestine but also
increased translocation of bacteria may impair liver homeostasis
and enhance liver inflammation through activation of the innate
immune system. Bacterial translocation is defined as the migra-
tion of viable bacteria or bacterial products from the intestinal
lumen to mesenteric lymph nodes or other extraintestinal organs
and sites (190). Recently, it has been demonstrated that during
HFD-induced diabetes in mice, commensal intestinal bacteria
translocate in pathological manner from intestine toward the tis-
sues where they trigger a local inflammation. This metabolic bac-
teremia was reversed by a Bifidobacterium animalis strain, which
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reduced the mucosal adherence and bacterial translocation of
Gram-negative bacteria from the Enterobacteriaceae group (191).
In particular, translocated bacterial products augment the acti-
vation of hepatic immune cells through pattern recognition recep-
tors including TLRs. Recently we demonstrated that, in a rat
model of steatosis and IR induced by high fat diet, gut barrier
integrity was altered (161). High fat diet induced an up-regulation
of transcription and expression of TLR4 and co-receptor CD14
or MyD88 at intestinal and liver level and an imbalance of Gram-
negative bacteria (Enterobacteriales and in particular E. coli). Gene
expression analysis revealed that in the liver of rats receiving
a Lactobacillus paracasei B21060-based synbiotic, TLR 2, 4 and
9, mRNAs expression was restored at physiological level. There-
fore, the hepatic inflammatory markers, such as TNFα, IL-6, and
NF-kB activation, were normalized, along with a restoration of
metabolic alterations through normalization of PPAR expression
and their target genes. Moreover, the synbiotic improved many
aspects of IR, such as fasting response, hormonal homeostasis,
glycemic control, and hepatic insulin signaling (161). Consistently
with our data, Ehses et al. (192) have reported that TLR2-deficient
mice are protected from IR and β cell dysfunction induced by
HFD, linking TLR2 to the increased dietary lipid and the alter-
ation of glucose homeostasis. Moreover, previous studies showed
that the administration of other probiotics (i.e., Lactobacillus and
Bifidobacterium) or prebiotics (i.e., inulin and oligofructose) can
modulate the microbiota and improve gut permeability, thus con-
trolling the occurrence of endotoxemia (193–197). Additional
carefully designed clinical studies based on experimental mech-
anistic data, are need to provide clinical evidence for the efficacy
in NAFLD therapy of probiotics and postbiotics (i.e., short chain
fatty acids) alone or in appropriate synergistic combination with
standard therapies.
CONCLUSION
The anatomical position of liver between gut and systemic cir-
culation, the hepatic cellular architecture, and the deep similarity
and interconnections between innate immune cells and those res-
ident in liver parenchyma have been highlighted, examining their
interplay in the development of liver damage and chronic disease.
Both cell types can modulate and interfere with critical processes
implicated in metabolic disease and inflammatory pathways, ini-
tiating and sustaining liver damage and its progression. Hence,
their cross-talk results to play a pivotal role in the development of
NAFLD, leading to the various spectrum of NAFLD pathologies.
Further studies are needed to confirm the real beneficial effects
of the therapeutic strategies to date available and their possible
associations. Moreover, new insights into the different signal-
ing pathways, evoked by innate response and liver inflammation,
could provide new insights on NAFLD pathoetiology, identifying
new potential therapeutic targets able, above all, to prevent its
progression.
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